https://serb.com/nl/news/randomized-double-blinded-study-to-commence-on-digifab-for-kidney-injury-related-to-cabg-surgery/ 2019-08-05T00:00:00+00:00 https://serb.com/nl/news/serb-pharmaceuticals-licenses-soligenix-antigen-to-develop-ricin-antidote/ 2022-08-04T10:41:37+00:00 https://serb.com/nl/news/serb-announces-the-acquisition-of-veriton-pharma/ 2022-08-24T16:28:00+00:00 https://serb.com/nl/news/young-epilepsy-and-veriton-pharma-ltd-announce-key-partnership-agreement-in-support-of-the-charitys-rules-4-schools-campaign/ 2022-08-24T16:29:11+00:00 https://serb.com/wp-content/uploads/2022/08/Young_Epilepsy.jpg https://serb.com/nl/news/epistatus-10-mg-oromucosal-solution-midazolam-now-available-to-prescribe/ 2022-09-08T01:13:07+00:00 https://serb.com/nl/news/thomas-kolaras-joins-serb-and-btg-specialty-pharmaceuticals-as-us-chief-commercial-officer/ 2022-09-08T08:56:28+00:00 https://serb.com/nl/news/serb-acquires-the-rights-to-xermelo-outside-us-and-japan-for-carcinoid-syndrome-diarrhoea/ 2022-09-08T08:57:32+00:00 https://serb.com/nl/news/serb-receives-eu-approval-for-voraxaze-glucarpidase-as-rescue-therapy-for-high-dose-methotrexate-toxicity/ 2022-09-08T08:58:36+00:00 https://serb.com/nl/news/first-evidence-of-high-dose-methotrexate-related-toxicity-in-spain-presented-at-virtual-ispor-europe-2021/ 2022-09-08T08:59:01+00:00 https://serb.com/nl/news/serb-receives-positive-chmp-opinion-for-voraxaze-glucarpidase-as-rescue-therapy-for-high-dose-methotrexate-toxicity/ 2022-09-08T08:59:55+00:00 https://serb.com/nl/news/ben-watt-joins-serb-and-btg-as-group-cfo/ 2022-09-08T09:00:10+00:00 https://serb.com/nl/news/btg-specialty-pharmaceuticals-advances-global-regulatory-program-for-glucarpidase-sold-as-voraxaze-in-the-us/ 2022-09-08T09:00:25+00:00 https://serb.com/nl/news/btg-specialty-pharmaceuticals-calls-on-consumers-and-retailers-to-consider-the-facts-about-venom-extractors/ 2022-09-08T09:00:38+00:00 https://serb.com/nl/news/serb-completes-acquisition-of-btg-specialty-pharmaceuticals-to-create-a-global-leader-in-critical-care-medicines/ 2022-09-08T09:00:59+00:00 https://serb.com/nl/news/boston-scientific-signs-definitive-agreement-to-divest-btg-specialty-pharmaceuticals-business/ 2022-09-08T09:01:15+00:00 https://serb.com/nl/news/initial-study-results-show-feasibility-of-outpatient-methotrexate-administration-with-planned-use-voraxaze-glucarpidase-during-covid-19-pandemic/ 2022-09-08T09:32:48+00:00 https://serb.com/nl/news/european-medicines-agency-has-accepted-for-review-a-marketing-authorisation-application-for-voraxaze/ 2022-09-08T09:33:45+00:00 https://serb.com/nl/news/study-underway-to-examine-the-planned-use-of-voraxaze-with-methotrexate-in-cns-lymphoma/ 2022-09-08T09:35:05+00:00 https://serb.com/nl/news/boston-scientific-closes-acquisition-of-btg-plc/ 2022-09-08T09:36:16+00:00 https://serb.com/nl/news/nccn-issues-first-pediatric-acute-lymphoblastic-leukemia-guidelines-including-use-of-voraxaze/ 2022-09-08T09:37:56+00:00 https://serb.com/nl/news/a-retrospective-study-of-medicare-claim-data-shows-patients-treated-with-voraxaze-had-shorter-hospitalizations-and-lower-mortality/ 2022-09-08T09:41:20+00:00 https://serb.com/nl/news/btg-and-omny-partner-to-improve-treatment-of-snake-bite-victims/ 2022-09-08T09:41:34+00:00 https://serb.com/nl/news/btg-announces-replacement-policy-for-expired-crofab/ 2022-09-08T09:41:51+00:00 https://serb.com/nl/news/fda-approves-crofab-product-improvements/ 2022-09-08T09:42:27+00:00 https://serb.com/nl/news/new-consensus-guidelines-provide-specific-recommendations-for-use-of-voraxaze-in-patients-with-dela/ 2022-09-08T09:43:12+00:00 https://serb.com/nl/news/vistogard-and-voraxaze-added-to-revised-guidelines-for-stocking-of-antidotes-in-us-hospitals/ 2022-09-08T09:43:56+00:00 https://serb.com/nl/news/new-data-from-largest-prospective-study-on-crofab-for-treatment-of-copperhead-snake-envenomation/ 2022-09-08T09:46:55+00:00 https://serb.com/nl/news/btg-announces-fda-approval-of-vistogard-uridine-triacetate-as-antidote-to-overdose-and-early-onset-severe-or-life-threatening-toxicities-from-chemotherapy-drugs-5-fluorouracil-5-fu/ 2022-09-08T09:47:35+00:00 https://serb.com/nl/news/btg-announces-fda-acceptance-of-wellstat-therapeutics-new-drug-application-for-uridine-triacetate-as-antidote-to-overexposure-to-chemotherapy-drug-5-fluorouracil-5-fu/ 2022-09-08T09:47:51+00:00 https://serb.com/nl/news/btg-reaches-settlement-regarding-crofab-patent-litigation/ 2022-09-08T09:48:04+00:00 https://serb.com/nl/news/btg-announces-data-presentation-on-voraxaze-glucarpidase-at-the-american-society-of-clinical-oncology-annual-meeting/ 2022-09-08T09:50:24+00:00 https://serb.com/nl/news/voraxaze-glucarpidase-launched-in-the-us/ 2022-09-08T09:50:45+00:00 https://serb.com/nl/news/btgs-manufacturing-facility-in-west-wales-awarded-top-environmental-standard/ 2022-09-08T09:52:02+00:00 https://serb.com/nl/news/digifab-40-mg-vial-digoxin-immune-fab/ 2022-09-08T09:54:17+00:00 https://serb.com/nl/news/btg-plc-voraxaze-glucarpidase-receives-us-regulatory-approval/ 2022-09-08T09:55:33+00:00 https://serb.com/nl/news/btg-plc-voraxaze-glucarpidase-licensed-to-ohara-pharmaceuticals-in-japan/ 2022-09-08T09:55:41+00:00 https://serb.com/nl/news/btg-plc-fda-accepts-biologics-license-application-file-for-voraxaze-glucarpidase-and-grants-priority-review/ 2022-09-08T09:56:20+00:00 https://serb.com/nl/news/btg-acquires-us-marketing-rights-to-wellstats-investigational-antidote-for-5-fu-overexposure/ 2022-09-08T10:02:06+00:00 https://serb.com/nl/news/btg-plc-astrazeneca-initiates-phase-iib-study-for-azd9773-cytofab-as-a-treatment-for-severe-sepsis/ 2022-09-08T10:02:25+00:00 https://serb.com/nl/news/btg-plc-astrazeneca-to-progress-cytofab-into-phase-iib-study/ 2022-09-08T10:04:00+00:00 https://serb.com/nl/news/btg-receives-first-european-regulatory-approval-for-digifab/ 2022-09-08T10:05:28+00:00 https://serb.com/nl/news/serb-presents-preclinical-data-showing-initial-efficacy-of-covid-19-treatment-developed-with-polyclonal-antibody-platform/ 2022-10-19T12:45:53+00:00 https://serb.com/nl/news/four-independent-studies-of-voraxaze-published-at-european-hematology-conference-2022/ 2023-03-22T15:59:01+00:00 https://serb.com/nl/news/trial-finds-patients-receiving-crofab-antivenom-less-likely-to-use-opioids-for-pain-control/ 2023-04-20T11:25:41+00:00 https://serb.com/nl/news/new-study-shows-patients-treated-with-crofab-have-improved-recovery-from-copperhead-envenomation/ 2023-04-20T11:27:17+00:00 https://serb.com/nl/news/new-research-validates-clinical-value-of-treating-copperhead-envenomation-with-crofab/ 2023-04-20T11:28:39+00:00 https://serb.com/nl/news/new-publication-compares-total-vials-of-crofabsup-sup-and-anavipsup-sup-administered-to-treat-us-rattlesnake-envenomation-2/ 2023-05-02T12:23:27+00:00 https://serb.com/nl/news/serb-pharmaceuticals-and-sfj-pharmaceuticals-announce-a-u-s-partnership-for-bentracimab-a-ticagrelor-reversal-agent/ 2023-05-23T15:37:51+00:00 https://serb.com/nl/news/new-publication-compares-total-vials-of-crofabsup-sup-and-anavipsup-sup-administered-to-treat-us-rattlesnake-envenomation/ 2023-05-23T15:38:22+00:00 https://serb.com/nl/news/new-economic-analysis-of-voraxaze-glucarpidase-in-patients-with-delayed-methotrexate/ 2023-05-23T15:39:06+00:00 https://serb.com/nl/news/btg-pharmaceuticals-statement-on-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-recommendation-for-use-of-glucarpidase-voraxaze-and-mtxpk-org-2/ 2023-06-22T12:32:26+00:00 https://serb.com/nl/news/btg-pharmaceuticals-statement-on-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-recommendation-for-use-of-glucarpidase-voraxaze-and-mtxpk-org/ 2023-06-22T14:34:29+00:00 https://serb.com/nl/news/serb-pharmaceuticals-acquires-vistogard-and-xuriden-from-wellstat-therapeutics/ 2023-07-13T12:12:43+00:00 https://serb.com/nl/news/btg-pharmaceuticals-a-serb-company-to-present-data-on-ricin-antidote-development-programme-at-the-north-american-congress-of-clinical-toxicology/ 2024-01-10T12:51:57+00:00 https://serb.com/nl/news/serb-pharmaceuticals-appoints-vanessa-wolfeler-as-ceo-to-drive-next-stage-of-the-companys-growth/ 2024-11-11T16:00:15+00:00 https://serb.com/nl/news/fda-has-accepted-a-bla-for-bentracimab-the-first-and-only-ticagrelor-reversal-agent-for-filing-and-priority-review/ 2024-11-11T16:01:33+00:00 https://serb.com/nl/news/serb-pharmaceuticals-strengthens-leadership-in-medical-countermeasures-with-the-global-acquisition-of-rsdl-reactive-skin-decontamination-lotion-kit-for-75-million/ 2024-11-11T16:01:53+00:00 https://serb.com/nl/news/serb-pharmaceuticals-grants-exclusive-license-to-m8-pharmaceuticals-an-acino-company-to-bring-voraxaze-glucarpidase-to-cancer-patients-in-latin-america/ 2024-11-11T16:02:21+00:00 https://serb.com/nl/news/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us/ 2024-12-09T13:23:16+00:00 https://serb.com/nl/news/serb-pharmaceuticals-expands-leading-emergency-care-portfolio-with-acquisition-of-aurlumyn-iloprost-iv-for-severe-frostbite/ 2025-03-28T13:02:32+00:00 https://serb.com/nl/news/sfj-pharmaceuticals-and-serb-pharmaceuticals-present-positive-final-results-from-pivotal-phase-3-reverse-it-trial-of-bentracimab-for-the-reversal-of-antiplatelet-effects-of-ticagrelor-in-patients-requ/ 2025-03-29T16:39:24+00:00 https://serb.com/nl/news/newly-published-study-shows-that-voraxaze-can-improve-clinical-outcomes-in-patients-with-high-dose-methotrexate-induced-acute-kidney-injury/ 2025-05-22T12:38:42+00:00 https://serb.com/nl/news/snakebite911-expands-free-snake-education-and-snakebite-safety-app-to-android-devices/ 2025-08-04T18:43:09+00:00 https://serb.com/nl/news/serb-pharmaceuticals-agrees-to-acquire-y-mabs-therapeutics/ 2025-08-05T18:17:56+00:00 https://serb.com/nl/news/cms-grants-vistogard-new-technology-add-on-payment-status-effective-1-october-2016/ 2025-09-01T16:27:28+00:00 https://serb.com/nl/news/cms-grants-new-prospective-reimbursement-for-voraxaze/ 2025-09-01T16:27:43+00:00 https://serb.com/nl/news/serb-pharmaceuticals-completes-acquisition-of-y-mabs-therapeutics/ 2025-09-16T12:45:26+00:00 https://serb.com/nl/news/dr-vignesh-rajah-appointed-as-serb-pharmaceuticals-chief-medical-officer/ 2026-01-16T14:34:46+00:00 https://serb.com/wp-content/uploads/2025/11/Vignesh_Rajah_transparent.png https://serb.com/wp-content/uploads/2022/08/Vignesh_Web.jpg?ver=1768561413 https://serb.com/nl/news/serb-pharmaceuticals-expands-scientific-leadership-with-appointment-of-dr-peter-c-adamson-to-us-board/ 2026-02-16T15:23:52+00:00 https://serb.com/wp-content/uploads/2026/02/Screenshot-2026-02-12-124214.png https://serb.com/nl/news/y-mabs-announces-update-to-national-comprehensive-cancer-network-nccn-clinical-practice-guidelines-in-oncology-for-neuroblastoma-to-include-naxitamab-gqgk-danyelza/ 2026-03-19T16:51:04+00:00 https://serb.com/nl/news/y-mabs-announces-partnership-regarding-early-access-program-for-danyelza-naxitamab-gqgk-in-europe/ 2026-03-19T16:51:05+00:00 https://serb.com/nl/news/fda-approves-y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-neuroblastoma/ 2026-03-19T16:51:05+00:00 https://serb.com/nl/news/y-mabs-signs-license-agreement-with-sciclone-for-danyelza-naxitamab-gqgk-and-omburtamab-in-china/ 2026-03-19T16:51:05+00:00 https://serb.com/nl/news/y-mabs-announces-publication-of-phase-2-interim-results-in-nature-communications/ 2026-03-19T16:57:23+00:00 https://serb.com/nl/news/y-mabs-and-nobelpharma-announce-exclusive-license-and-distribution-agreement-for-danyelza-naxitamab-gqgk-in-japan/ 2026-03-19T16:59:00+00:00 https://serb.com/nl/news/y-mabs-presents-neuroblastoma-research-on-naxitamab-and-sada-prit-technology-platform-at-aacr-special-conference-on-advances-in-pediatric-cancer-research/ 2026-03-19T16:59:15+00:00 https://serb.com/nl/news/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-brazil/ 2026-03-19T17:00:18+00:00 https://serb.com/nl/news/y-mabs-and-the-european-medicines-agency-reach-agreement-on-the-pediatric-investigation-plan-for-naxitamab/ 2026-03-19T17:00:32+00:00 https://serb.com/nl/news/y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-high-risk-neuroblastoma-approved-in-china/ 2026-03-19T17:00:48+00:00 https://serb.com/nl/news/y-mabs-and-takeda-announces-marketing-authorization-in-israel-for-danyelza-naxitamab-gqgk-for-neuroblastoma/ 2026-03-19T17:01:08+00:00 https://serb.com/nl/news/y-mabs-announces-naxitamab-chemoimmunotherapy-investigational-trial-for-high-risk-neuroblastoma-meets-primary-endpoint/ 2026-03-19T17:01:36+00:00 https://serb.com/nl/news/y-mabs-announces-frontline-data-for-danyelza-naxitamab-gqgk-in-high-risk-neuroblastoma/ 2026-03-19T17:01:53+00:00 https://serb.com/nl/news/y-mabs-enters-into-exclusive-distribution-agreement-with-adium-pharma-s-a-for-danyelza-naxitamab-gqgk-and-omburtamab-in-latin-america/ 2026-03-19T17:02:10+00:00 https://serb.com/nl/news/y-mabs-signs-distribution-agreement-with-swixx-for-danyelza-naxitamab-gqgk-and-omburtamab-in-eastern-europe/ 2026-03-19T17:02:24+00:00 https://serb.com/nl/news/y-mabs-announces-update-on-danyelza-naxitamab-gqgk-at-esmo/ 2026-03-19T17:02:42+00:00 https://serb.com/nl/news/y-mabs-and-takeda-announce-exclusive-license-and-distribution-agreement-for-danyelza-naxitamab-gqgk-and-omburtamab-in-israel/ 2026-03-19T17:03:47+00:00 https://serb.com/nl/news/y-mabs-announces-update-on-naxitamab-and-omburtamab-in-neuroblastoma/ 2026-03-19T17:04:03+00:00 https://serb.com/nl/news/y-mabs-announces-u-s-fda-acceptance-of-biologics-license-application-for-danyelza-naxitamab-for-the-treatment-of-neuroblastoma-for-priority-review/ 2026-03-19T17:04:21+00:00 https://serb.com/nl/news/y-mabs-announces-submission-of-naxitamab-biologics-license-application-to-u-s-fda/ 2026-03-19T17:04:47+00:00 https://serb.com/nl/news/y-mabs-announces-publication-in-cancers/ 2026-05-05T12:18:41+00:00 https://serb.com/nl/news/serb-pharmaceuticals-announces-thyrosafe-130mg-potassium-iodide-tablets-are-now-commercially-available-in-the-us/ 2026-05-07T12:03:08+00:00 https://serb.com/nl/news/serb-pharmaceuticals-to-acquire-european-and-mena-rights-to-idefirix-imlifidase-from-hansa-biopharma-for-e115-million/ 2026-06-12T13:23:59+00:00